the authors constructed a very nice model predicting the mortality risk while on veno-venous extra-corporeal membrane oxygenation (vvECMO) in patients with acute respiratory distress syndrome (ARDS) due to H1N1 pneumonia. These patients were analyzed retrospectively from a large Italian vvECMO network [2] . Until publication of this paper, inclusion and exclusion criteria for vvECMO treatment were based on expert opinion [3] . The authors constructed the model from the retrospective data of 60 patients, of which 82 % had H1N1 pneumonia with a survival rate of 71 %. The remaining ARDS patients had a survival rate of 52 %. In another validation set containing 74 patients, the authors tested their model: the area under the curve (AUC) of the receiver operating characteristic (ROC) was 0.69 to predict mortality while on ECMO with a ECMOnet score [4.5 points, with a sensitivity of 51 % and a specificity of 76 %.
Dear Editor, We read with great interest the paper of Pappalardo et al. [1] . In this paper, the authors constructed a very nice model predicting the mortality risk while on veno-venous extra-corporeal membrane oxygenation (vvECMO) in patients with acute respiratory distress syndrome (ARDS) due to H1N1 pneumonia. These patients were analyzed retrospectively from a large Italian vvECMO network [2] . Until publication of this paper, inclusion and exclusion criteria for vvECMO treatment were based on expert opinion [3] . The authors constructed the model from the retrospective data of 60 patients, of which 82 % had H1N1 pneumonia with a survival rate of 71 %. The remaining ARDS patients had a survival rate of 52 %. In another validation set containing 74 patients, the authors tested their model: the area under the curve (AUC) of the receiver operating characteristic (ROC) was 0.69 to predict mortality while on ECMO with a ECMOnet score [4.5 points, with a sensitivity of 51 % and a specificity of 76 %.
In our center, we have treated 44 patients with vvECMO: 50 % for bacterial pneumonia, 20 % for viral pneumonia and 27 % for autoimmune pneumonitis disease. The overall survival rate while on vvECMO was 73 %. When applying the ECMOnet score to our patients, the optimal cut-off point (calculated with the Youden index) was an ECMOnet score of 6.5. The AUC with an ECMOnet score [6.5 was exactly 0.69 for predicting mortality while on ECMO with a sensitivity of 50 % and a specificity of 80 % (see Fig. 1 ). AUC of the oxygenation index and APACHEII was 0.52 and 0.54, respectively. Therefore, it seems that the ECMOnet score is a promising scoring system with a fair specificity in predicting mortality while on vvECMO, although with a higher cut-off point. At least, the ECMOnet score is much better than traditional scoring systems such as oxygenation index or APACHEII.
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